A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder

Repeated Psilocybin doses approximately once per week over the course of the 8-week protocol may be effective in treating OCD

In this study Moreno et al. (2026) conducted a small randomized controlled trial examining repeated doses of psilocybin for treatment-resistant obsessive-compulsive disorder. In the initial double-blind phase, participants receiving psilocybin showed significantly greater reductions in OCD symptoms (measured by Y-BOCS) compared with an active placebo, with effects appearing rapidly after dosing.

Across the full 8-week protocol, including repeated high-dose administrations, around three-quarters of participants met responder criteria and approximately 40% achieved remission. Symptom improvement appeared to accumulate with repeated dosing and was partially sustained at 6-month follow-up, although some attenuation was observed over time. The intervention was generally well tolerated, with no serious adverse events or psychotic reactions reported. Despite these promising findings, the authors emphasise important limitations, particularly the very small sample size and challenges with blinding, and conclude that larger trials are needed before clinical application can be considered.

“Background:

Current treatments for obsessive–compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed.

Aims:

This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses in OCD patients.

Methods:

Fifteen participants were randomized to receive 4 weekly sessions of high-dose (300 µg/kg), low-dose (100 µg/kg) psilocybin, or active placebo (lorazepam) in a double-blind Phase 1 (n = 5 per condition), followed by four additional high-dose sessions (single-blind Phase 2). OCD severity was assessed with the Yale-Brown Obsessive Compulsive Scale (YBOCS) following each session, and prospectively for 6 months. Safety was evaluated via adverse event systematic assessment, suicide severity rating, and psychosis screening.

Results:

Psilocybin was generally well-tolerated, with no serious adverse events, or psychotic symptoms, and no significant changes in suicide severity scores. Psilocybin but not placebo significantly reduced YBOCS scores. At the end of 8-week treatment, after participants had received at least four high doses of psilocybin, 73.3% were responders (⩾35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6 months. Post hoc analysis of cumulative dosing correlated with YBOCS score reductions at the end of treatment.

Conclusions:

Administration of up to eight doses of psilocybin in a clinical research setting appears to be safe and potentially effective for patients with OCD. Larger trials are needed to further support efficacy and refine treatment protocols. “

Moreno FA, Allen KE, Wiegand CB, et al. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder. Journal of Psychopharmacology. 2026;0(0). Read Paper

For more psychedelic news and research, visit the psychedelic health professional network homepage.